NewLink Genetics Corp., through its wholly owned subsidiary BioProtection Systems Corp., today announced a letter contract with the U.S. Defense Threat Reduction Agency for studies that will bring an Ebola vaccine licensed from the Public Health Agency of Canada closer to human clinical trials. The Ames-based company said the contract provides $1 million in funding, with additional funding subject to final negotiation. The vaccine has been 100 percent effective in preventing lethal infection in non-human primates, and also acts rapidly enough to have significant efficacy even when given to animals that recently received a lethal dose of the virus, said Dr. Charles Link, the company's chairman and CEO.